Rakovina Therapeutics Inc (V:RKV) — Market Cap & Net Worth
Market Cap & Net Worth: Rakovina Therapeutics Inc (RKV)
Rakovina Therapeutics Inc (V:RKV) has a market capitalization of $1.68 Million (CA$2.33 Million) as of July 25, 2026. Listed on the V stock exchange, this Canada-based company holds position #30164 globally and #1511 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Rakovina Therapeutics Inc's stock price CA$0.11 by its total outstanding shares 21148039 (21.15 Million). Review how much debt does Rakovina Therapeutics Inc carry to assess the company's total debt and financial obligations.
Rakovina Therapeutics Inc Market Cap History: 2021 to 2026
Rakovina Therapeutics Inc's market capitalization history from 2021 to 2026. Data shows change from $3.37 Million to $1.68 Million (-14.31% CAGR).
Rakovina Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Rakovina Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of RKV by Market Capitalization
Companies near Rakovina Therapeutics Inc in the global market cap rankings as of July 25, 2026.
Key companies related to Rakovina Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #427 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- Samsung Biologics Co Ltd (KO:207940): Ranked #560 globally with a market cap of $47.62 Billion USD ( ₩70.27 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.36 |
| #427 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $656.01 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €804.40 |
| #560 | Samsung Biologics Co Ltd | KO:207940 | $47.62 Billion | ₩1518000.00 |
Rakovina Therapeutics Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Rakovina Therapeutics Inc's market cap moved from $3.37 Million to $ 1.68 Million, with a yearly change of -14.31%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$1.68 Million | +10.00% |
| 2025 | CA$1.53 Million | -47.37% |
| 2024 | CA$2.91 Million | +123.53% |
| 2023 | CA$1.30 Million | -52.78% |
| 2022 | CA$2.75 Million | -18.18% |
| 2021 | CA$3.37 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 25th, 2026 the market cap of Rakovina Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.68 Million USD |
| MoneyControl | $1.68 Million USD |
| MarketWatch | $1.68 Million USD |
| marketcap.company | $1.68 Million USD |
| Reuters | $1.68 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Rakovina Therapeutics Inc
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company's preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series … Read more